A pilot study to examine the safety of combination with selective COX2 inhibitor meloxicam before autologous peripheral blood stem cell harvest and the collection efficiency of hematopoietic stem cells
Not Applicable
Recruiting
- Conditions
- Patients with multiple myeloma who receive autologous peripheral blood stem cell harvest
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 5
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients who are not eligible for apheresis 2)Allergy to meloxicam 3)Patients who cannot take medicine orally on the 10th day after the administration of the anticancer drug 4)Patients with bleeding tendency before treatment 5)Patients who are difficult to maintain platelets more than 20,000/mm3 even if appropriate measures such as platelet transfusion are done 6)Patients with active gastrointestinal ulcer 7)Patients with severe renal dysfunction (G3b or more in GFR classification) 8)Patients with aspirin-induced asthma or a history of aspirin-induced asthma 9)Inadequate condition as diagnosed by primary physician
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cumulative incidence and severity of bleeding, gastrointestinal ulcer and renal dysfunction and analgesic effect
- Secondary Outcome Measures
Name Time Method The collection efficiency of hematopoietic stem cells